Glaukos Corp. (NYSE:GKOS) Announces Record Q3 Sales, Raises Guidance

October 29, 2025 — Leads & Copy — Glaukos Corporation (NYSE: GKOS) reported its third-quarter financial results, revealing a record net sales of $133.5 million, a 38% increase year-over-year.

Glaucoma net sales reached $110.2 million, up 45% from the previous year, with U.S. Glaucoma net sales hitting $80.8 million, a 57% increase. The gross margin was approximately 78%, and the non-GAAP gross margin was about 84%.

The company has raised its 2025 net sales guidance to $490 million to $495 million and introduced preliminary 2026 net sales guidance of $600 million to $620 million.

Thomas Burns, Glaukos chairman and CEO, attributed the results to the successful global execution of key strategic plans.

The company will host a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. The webcast can be accessed on the company’s website.

Contact:

Source: Glaukos Corporation

Source: Glaukos Corporation

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.